Increasing investments in research and development in genomic studies, technological enhancements in genetic sequencing and target gene selection, increasing prevalence of cancer, cost effectiveness and reduced side effects are the driving forces of this market. Monoclonal antibodies are highly acceptable therapeutic agents worldwide and are one of the best selling drugs in 2010.
The market is predicted to grow lucratively in the coming six years due to presence of strong product pipeline for monoclonal antibodies. Around 300 mAbs (monoclonal antibodies) presently are in clinical development stage.
The market is predicted to grow lucratively in the coming six years due to presence of strong product pipeline for monoclonal antibodies. Around 300 mAbs (monoclonal antibodies) presently are in clinical development stage.
The market for monoclonal antibodies has been divided into two segments globally which are on the basis of applications and region. The antibodies are used for the treatment of various diseases such as autoimmune diseases, cancer and inflammatory diseases. mAbs (monoclonal antibodies) are specific in nature and they interact with the cells without entering inside and are expected to play vital role in clinical protocols in the forecast period.
The monoclonal antibodies market is globally classified in North America, Europe, Asia-Pacific & RoW. North America is expected to hold the maximum market share in this market. The developing economies in Middle East & Asia Pacific are expected to have a relevant growth in this market owing to huge untapped potential, rising disposable income, increasing patient awareness & increased expenditure in research & development.
The key players that contribute to the global market of prokaryotic expression system are Genentech, Abbott Laboratories, Amgen Inc, AstraZeneca plc, Elan Corporations plc, Human Genome Sciences, Daiichi Sankyo, GlaxoSmithKline plc, Eisai Co. Ltd, Johnson & Johnson, Eli Lilly Roche, Merck & Co Inc, Eli Lilly, Biogen Idec Inc, Bayer AG, Alexion Pharmaceuticals, Novartis International, Pfizer and Bristol Myers Squibb. Roche is the market leader in producing a genetically engineered drug that controls the abnormal growth of Her2 (responsible for breast cancer).
Request TOC of “Monoclonal Antibodies Market Analysis"
No comments:
Post a Comment